Compare Dollar Tree, Inc. (DLTR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Incyte Corporation — how do they compare? Dollar Tree, Inc. trades at $128.64 (market cap $24.61B), while Incyte Corporation trades at $121.3 (market cap $24.54B). The key difference: Dollar Tree, Inc. and Incyte Corporation are close in size by market cap. Which is the better fit depends on your goals.
| DLTR | INCY | |
|---|---|---|
Market Cap | $24.61B | $24.54B |
Sector | Health | Health |
52-Week High | $141.21 | $129.93 |
52-Week Low | $85.04 | $81.61 |
Enterprise Value | $31.20B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $129.37, down 1.17% today but remains in a bullish technical trend with strong support near $128. The company reported a net loss of $3.03B for 2025 due to a significant tax charge, though operating cash flow improved to $2.86B. Recent earnings have consistently beaten estimates, and a new $2.5B share repurchase program signals management confidence.
The outlook is mixed: robust cash generation and positive earnings surprises support upside, but margin pressures from tariffs and intense discount retail competition pose risks. Analyst consensus is a Buy with a $126.69 price target, slightly below current levels, indicating cautious optimism amid operational challenges.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
